Gracell Biotechnologies Inc. (GRCL) Tops Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts GRCL Hot Sheet
Join SI Premium – FREE
Gracell Biotechnologies Inc. (NASDAQ: GRCL) reported Q3 EPS of ($0.07), $0.06 better than the analyst estimate of ($0.13).
For earnings history and earnings-related data on Gracell Biotechnologies Inc. (GRCL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
- Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
- Lument Finance Trust (LFT) Misses Q2 EPS by 17c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
